New immunotherapy targets Hard-to-Treat KRAS cancers in early trial
NCT ID NCT04853017
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This early-phase trial tested a new immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy combines an immune booster with cancer-specific peptides to train the body's immune system to attack cancer cells. The main goal was to check safety and see if the treatment could reduce tumor DNA in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Northwell Health
Lake Success, New York, 11042, United States
-
Tennessee Oncology - Centennial Clinic
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ELI-002 immunotherapy (a combination of an immune-boosting compound and cancer-targeting peptides)
What this could lead to
If successful, this could lead to a new treatment option for people with certain KRAS-mutated cancers, especially those with minimal residual disease after standard therapy.
What could go wrong
This is a very early (Phase 1) and small (25 participants) trial focused on safety. It may not show strong anti-cancer effects, and the treatment may cause side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.